A Phase 1B, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

Protocol No
NEKTAR-16-214-05
Principal Investigator
Matthew Riese
Phase
I
Summary
This is an investigational study of a drug named NKTR-214 that will be given in combination with pembrolizumab (KEYTRUDA®) or atezolizumab (TECENTRIQ® (pronounced tē-SENtrik ). NKTR-214, also referred to as study drug , is a modified (changed in the laboratory) form of a protein called interleukin-2 (or IL-2) that is normally made by your immune system. This protein is designed to trigger (wake up) other cells in your immune system to start attacking your cancer cells. IL-2 has been used for certain cancers for many years so doctors understand many of the risks and benefits. NKTR-214 has not been approved to treat cancer by the U.S. FDA or any other health or regulatory authority in other countries.
Description
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: